We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Victoria
Parker
v.parker@sheffield.ac.uk
SCS
ResearchWPH
sth.specialisedcancerresearchadministration@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms of female genital organsNeoplasms of uncertain or unknown behaviourPregnancy with abortive outcome
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
GTD is a serious complication of pregnancy, most commonly discovered in the first 12-weeks. Where present, the pregnancy cannot continue, and patients must have surgery. In the UK, ~1,800 patients are diagnosed with GTD every year. As the condition is fairly rare, healthcare professionals may not have the experience to diagnose or support patients. Patients often make many visits to hospitals for scans and blood tests before the diagnosis is suspected. Once diagnosed, patients come under a specialist centre. For ~6 months, patients send regular urine or blood samples to monitor the condition. One in ten patients develop GTN. This is cancerous and patients need chemotherapy at a specialist centre in Sheffield or London, with regular appointments and blood tests during this time. GTD patients should wait until the end of monitoring before trying to get pregnant again. GTN patients should wait even longer; one year after the end of chemotherapy.
Patients can find the experience of GTD and GTN devastating and overwhelming. It has physical, psychological and financial implications. Our PPI co-applicants discussed feeling post-traumatic stress from the experience. Some felt that issues with the healthcare pathway had worsened the trauma they experienced from the disease. In contrast, others felt their healthcare had been good. This indicates that current support is inconsistent, and improvements can be made. Therefore, we need to explore patients’ stories to know how to improve the pathways and experience.
We will speak to 30 patients who have experienced GTD and GTN in the last two years and recruit them via specialist hospitals in Sheffield and London. We will also speak to ~16 healthcare professionals from across the UK. Using the findings from this research, we will suggest improvements to healthcare services and hold workshops with patients, healthcare professionals, and other partners to discuss these improvements.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
- Patients with inconclusive diagnosis/histology, not suggestive of GTD/GTN. - HCPs who are not involved in the diagnosis or treatment of GTD/GTN patients. - Healthcare professionals who do not work in Early Pregnancy Units or specialist trophoblastic centres in the UK. - Participants who lack capacity to give informed consent. - Patients who are not considered clinically well-enough to participate. - Patients under the age of 16 years.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
SCS
ResearchWPH
sth.specialisedcancerresearchadministration@nhs.net
Victoria
Parker
v.parker@sheffield.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 64977
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
